AngioDynamics Inc. a provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, has acquired Eximo Medical Ltd., an early commercial stage, medical device company, and its proprietary 355nm wavelength laser-technology platform for $46 million in up-front consideration with up to $20 million of contingent consideration related to certain technical and revenue milestones.
\nThe transaction is being funded exclusively through the use of cash on hand, officials.
\n\u201cThe acquisition of Eximo brings a remarkable, foundational technology to our portfolio that will change the way caregivers deliver treatment to patients with PAD,\u201d said Jim Clemmer, president and chief executive officer of AngioDynamics, Inc. \u201cThe market is ripe for disruption, and the level of precision, safety, and efficiency offered to physicians by this laser technology creates a substantially differentiated alternative to legacy atherectomy devices.\u201d
\nPhysicians provide atherectomy treatment to over 200,000 Americans annually, and Eximo\u2019s laser technology represents a technological breakthrough among medical devices used in atherectomy procedures to treat PAD.
\nIn acquiring Eximo and its laser technology, AngioDynamics enters a growing $500-plus million market with an innovative medical solution that offers greater versatility, a wider range of treatments, and strong clinical data to support its efficacy, officials said.
\nDifferentiated from other legacy medical devices, Eximo\u2019s laser technology is the only system capable of delivering short, high-powered pulsed-laser energy in 355nm wavelength without compromising the integrity of its fiber optic cables during atherectomy procedures. The technology addresses the risk of perforation through tissue selectivity, addresses the risk of embolization to the patient through the availability of aspiration and is indicated to provide treatment for In-Stent Restenosis (ISR), which is the gradual re-narrowing of the artery after a blockage has been previously treated with a stent.
\nAdditionally, officials said, Eximo\u2019s laser technology advances patient treatment options and care by treating a variety of PAD lesion types both above- and below-the-knee.
\nAngioDynamics said the technology is a safe, fast, and effective system that clinical studies have shown to be effective in treating lesions ranging from soft plaque to severely calcified.
\n\u201cWe are very happy to join AngioDynamics\u201d, said Yoel Zabar, chief executive officer of Eximo Medical, Ltd. \u201cWe believe that AngioDynamics\u2019 existing resources and commercial acumen will enable a large number of patients to benefit from Eximo\u2019s laser technology, and we look forward to extending its utility into other indications within vascular and elsewhere. We would also like to thank the number of physicians that have already partnered with us during our journey, and we look forward to continuing our work together as we expand our physician base.\u201d
\nAngioDynamics\u2019 product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products.
\nFor more information, visit www.angiodynamics.com.<\/p>\n","protected":false},"excerpt":{"rendered":"
AngioDynamics Inc. a provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, has acquired Eximo Medical Ltd., an early commercial stage, medical device company, and its proprietary 355nm wavelength laser-technology platform for $46 million in up-front consideration with up to $20 million of contingent consideration related to certain technical […]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"yoast_head":"\r\n